European Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bnEuropean Commission funds NUDZ·$0.22mLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnPfizer buys Metsera·no dollar priceAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·no dollar priceAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 23 · Tue 17 Nov 

Companies

Gilgamesh

Gilgamesh Pharmaceuticals, Inc.

HQ
United States
Status
acquired
Listing
Private

sec.govregistryverified 2026-11-02

Notes on the record

Target in D003-abbvie-gilgamesh-2025 and counterparty to the 2024 option in D004-abbvie-gilgamesh-option-2024. Lead programme bretisilocin (GM-2505), renamed ABBV-2505 after the acquisition closed in October 2025. Added 2026-09-25 so the deal tape can print its short name. RE-VERIFIED 2026-11-02, no field changed: source 10-K HTTP 200; AbbVie Q3 2026 EX-99.1 (2026-10-30) has 0 hits for Gilgamesh. Supersedes the row verified 2026-09-25 (kept), per DATA LAYER rule 4.

Assets

No asset in data/assets.csv names this company as owner.

Registered trials

No row in data/trials.csv resolves to this company's assets.

Deals

In the briefing

No published issue carries the GILGAMESH tag.

Record history